[Clinical evaluation of MMC-mc-chemoembolization therapy and its combination with UFT in hepatocellular carcinoma].
A retrospective comparative study was done on the management of hepatoma: MMC-mc-chemoembolization therapy (group A; 9 patients) vs. the same therapy in combination with UFT as a maintenance therapy (group B; 8 patients). The six-month survival rate was 44.4% for group A, and 87.5% for group B. Generalized Wilcoxon test for the whole period revealed that the survival was favorable for group B as compared with A (P = 0.048). For adverse reactions in UFT therapy, no subjective signs occurred, but objective ones appeared such as one case of leukocytopenia, one of thrombocytopenia and 3 of increased GOT. However, no cessation of UFT therapy was necessary in these patients. These findings suggested that maintenance therapy with UFT may be favorable in this type of treatment for hepatoma.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D004334:Drug Administration Schedule; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil